重组人血管内皮抑制素注射液联合GP化疗方案治疗晚期NSCLC的可行性  

Feasibility of recombinant human endostatin injection combined with GP chemotherapy regimen in the treatment of advanced NSCLC

作　　者：宋永波[1] 赵璐[1] 张艳苓[1] 任武[1] SONG Yongbo;ZHAO Lu;ZHANG Yanling;REN Wu(Department of Medical Oncology,Wanbei Coal-electricity Group General Hospital,Anhui Province,Suzhou 234000,China)

机构地区：[1]皖北煤电集团总医院肿瘤内科,安徽省宿州市234000

出　　处：《临床合理用药杂志》2024年第12期13-16,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察重组人血管内皮抑制素注射液联合GP化疗方案治疗晚期非小细胞肺癌(NSCLC)的可行性。方法回顾性选取2020年5月—2022年12月皖北煤电集团总医院肿瘤内科收治的晚期NSCLC患者80例,将采用GP化疗方案治疗者纳入GP化疗组(n=40),重组人血管内皮抑制素注射液联合GP化疗方案治疗者纳入联合用药组(n=40),2组均以3周为1个治疗周期,共治疗2个周期。比较2组患者近期疗效,用药前后实验室指标、生活质量评分,不良反应及1年存活率。结果联合用药组客观缓解率为85.00%,高于GP化疗组的52.50%(χ^(2)=9.833,P=0.002)。用药2个周期后,2组血清癌胚抗原、糖类抗原125水平低于用药前,凝血酶时间、活化部分凝血活酶时间短于用药前,凝血酶原时间长于用药前,血浆纤维蛋白原、D-二聚体水平高于用药前,且联合用药组各指标优于对照组(P<0.05或P<0.01);2组生理功能、躯体功能、精神状态、社会关系评分高于用药前,且联合用药组高于GP化疗组(P<0.01)。联合用药组与GP化疗组不良反应总发生率分别为22.50%、15.00%,组间比较差异无统计学意义(χ^(2)=0.738,P=0.390)。联合用药组1年存活率为65.00%,高于GP化疗组的42.50%(χ^(2)=4.073,P=0.044)。结论晚期NSCLC治疗中采用重组人血管内皮抑制素注射液联合化疗药物的可行性较高,可有效降低肿瘤标志物水平,延缓病情进展,提高患者生活质量及1年存活率,且具有一定安全性。Objective To observe the feasibility of recombinant human endostatin injection combined with GP chemotherapy regimen in the treatment of advanced NSCLC.Methods A total of 80 patients with advanced NSCLC admitted to the Department of Medical Oncology of Wanbei Coal-electricity Group General Hospital from May 2020 to December 2022 were retrospectively selected,and 40 cases treated with GP chemotherapy regimen were included in the GP chemotherapy group,and 40 cases treated with recombinant human endostatin injection combined with GP chemotherapy regimen were included in the combination group,the two groups were taken 3 weeks as a treatment cycle,and a total of 2 cycles of treatment.Clinical efficacy,laboratory indexes,quality of life score before and after medication,incidence of adverse reactions and 1-year survival rate of the patients in the two groups were compared.Results The objective remission rate of the combination group was 85.00%,which was higher than 52.50%of the GP chemotherapy group(χ^(2)=9.833,P=0.002).After 2 cycles of medication,serum CEA and CA125 levels of the two groups were lower than those before medication,TT and APTT were shorter than those before medication,PT was longer than that before medication,plasma Fib and D-D levels were higher than those before medication,and the indicators of the combination group were better than those in the GP chemotherapy group(P<0.05 or P<0.01);Scores of physiological function,somatic function,mental state and social relationship of the two groups were higher than those before medication,and the combination group were higher than those of the GP chemotherapy group(P<0.01).The total incidence of adverse reactions in the combination group and the GP chemotherapy group was 22.50%and 15.00%,respectively,and the difference between the two groups was not statistically significant(χ^(2)=0.738,P=0.390).The 1-year survival rate in the combination group was 65.00%,which was higher than 42.50%of the GP chemotherapy group(χ^(2)=4.073,P=0.044).Conclusion Recombinant hum

关 键 词：非小细胞肺癌 晚期 GP化疗方案 重组人血管内皮抑制素注射液 肿瘤标志物 凝血功能 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]